Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147724 | 0.85 | ILK (0.68) | ILKALDH1A1GAALMNAMAPT | |
| SCHEMBL5146319 | 0.82 | ILK (0.73) | ILKALDH1A1GAALMNAMAPT | |
| SCHEMBL5146269 | 0.82 | ILK (0.77) | ILKALDH1A1GAALMNAMAPT | |
| SCHEMBL5147602 | 0.79 | ILK (1.00) | ILKALDH1A1GAALMNAMAPT | |
| SCHEMBL5146303 | 0.75 | ILK (1.00) | ILKALDH1A1GAALMNAMAPT | |
| SCHEMBL5147557 | 0.74 | ILK (0.74) | ILKALDH1A1GAALMNAMAPT | |
| SCHEMBL5148534 | 0.74 | ILK (0.56) | ILKALDH1A1GAALMNAMAPT | |
| SCHEMBL11207069 | 0.70 | ILK (0.54) | ILKALDH1A1GAALMNAMAPT | |
| SCHEMBL22609331 | 0.69 | ILK (0.57) | ILKALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL22609262 | 0.69 | ILK (0.57) | ILKALDH1A1LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288556-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7288556-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7288556-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7022702-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060009500-A1 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| US-20030096848-A1 | Antiproliferative 1,2,3-thiadiazole compounds | DERMIRA (CANADA), INC. | 2003-05-22 | — | — | US | disclosed |
| US-6420400-B1 | ANTITUMOR, ANGIOGENESIS INHIBITOR, CONTROLLING CELL PROLIFERATION | KINETEK PHARMACEUTICALS, INC. (CA) | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096848-A1 | Antiproliferative 1,2,3-thiadiazole compounds | CCNA1, CCND1, CCND3 | ILK 1286/4885ALDH1A1 1001/4885GAA 3900/4885 |
| US-20060009500-A1 | Antiproliferative 1,2,3-thiadiazole compounds | CCNA1, CCND3, ACIN1 | ILK 2862/4885ALDH1A1 715/4885GAA 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.